25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RYTM (Rhythm Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Rhythm Pharmaceuticals Inc together

I guess you are interested in Rhythm Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Rhythm Pharmaceuticals Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Rhythm Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Rhythm Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Rhythm Pharmaceuticals Inc

I send you an email if I find something interesting about Rhythm Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Rhythm Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Rhythm Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.04
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$2.56
Expected worth in 1 year
$4.16
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$1.64
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
$86.70
Expected price per share
$58.71 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Rhythm Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$86.70
Intrinsic Value Per Share
$-25.04 - $-1.62
Total Value Per Share
$-22.48 - $0.95

2.2. Growth of Rhythm Pharmaceuticals Inc (5 min.)




Is Rhythm Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$163m$152.7m-$58.2m-61.6%

How much money is Rhythm Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$42.5m-$68.4m$25.9m61.1%
Net Profit Margin-125.3%-288.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Rhythm Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#269 / 872

Most Revenue
#184 / 872

Most Profit
#758 / 872

Most Efficient
#534 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Rhythm Pharmaceuticals Inc?

Welcome investor! Rhythm Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Rhythm Pharmaceuticals Inc.

First you should know what it really means to hold a share of Rhythm Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Rhythm Pharmaceuticals Inc is $86.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rhythm Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rhythm Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.56. Based on the TTM, the Book Value Change Per Share is $0.40 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.62 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rhythm Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.78-0.9%-0.67-0.8%-1.08-1.2%-0.82-0.9%-0.67-0.8%-0.47-0.5%
Usd Book Value Change Per Share-0.020.0%0.400.5%-0.62-0.7%-0.10-0.1%-0.07-0.1%0.060.1%
Usd Dividend Per Share0.000.0%0.010.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.020.0%0.410.5%-0.62-0.7%-0.09-0.1%-0.07-0.1%0.070.1%
Usd Price Per Share52.97-50.60-32.18-33.89-27.79-20.03-
Price to Earnings Ratio-17.02--19.09--9.08--11.67--9.47--8.84-
Price-to-Total Gains Ratio-2,308.24--633.30--15.74--226.62--148.89--114.38-
Price to Book Ratio20.66-101.48-18.78-41.68-26.99-15.42-
Price-to-Total Gains Ratio-2,308.24--633.30--15.74--226.62--148.89--114.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share86.7
Number of shares11
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.40-0.07
Usd Total Gains Per Share0.41-0.07
Gains per Quarter (11 shares)4.50-0.76
Gains per Year (11 shares)18.01-3.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101880-3-13
2135260-6-16
3153440-9-19
4270620-12-22
5288800-16-25
63105981-19-28
731231161-22-31
841401341-25-34
941581521-28-37
1051761701-31-40

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%2.043.02.04.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%11.025.04.027.5%13.028.06.027.7%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.046.02.1%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%11.025.04.027.5%13.028.06.027.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Rhythm Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0230.399-106%-0.622+2609%-0.095+315%-0.071+208%0.064-136%
Book Value Per Share--2.5631.486+72%2.401+7%2.554+0%3.233-21%2.563+0%
Current Ratio--3.3024.140-20%5.665-42%5.963-45%9.187-64%10.692-69%
Debt To Asset Ratio--0.5780.756-24%0.527+10%0.532+9%0.362+60%0.293+98%
Debt To Equity Ratio--1.37110.720-87%1.414-3%4.197-67%2.567-47%1.353+1%
Dividend Per Share---0.010-100%-0%0.003-100%0.002-100%0.001-100%
Enterprise Value--3460922855.0003245846150.000+7%2143627343.125+61%2262081382.292+53%1930454522.625+79%1876210387.583+84%
Eps---0.778-0.668-14%-1.076+38%-0.818+5%-0.665-14%-0.465-40%
Ev To Ebitda Ratio---18.408-22.067+20%-10.611-42%-13.727-25%-12.062-34%-14.918-19%
Ev To Sales Ratio--26.45623.803+11%22.746+16%32.489-19%861.232-97%861.232-97%
Free Cash Flow Per Share---0.634-0.289-54%-0.713+12%-0.544-14%-0.555-12%-0.390-39%
Free Cash Flow To Equity Per Share---0.1230.574-122%-0.403+227%0.126-198%-0.021-83%0.212-158%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.617----------
Intrinsic Value_10Y_min---25.041----------
Intrinsic Value_1Y_max---1.358----------
Intrinsic Value_1Y_min---2.247----------
Intrinsic Value_3Y_max---3.169----------
Intrinsic Value_3Y_min---7.018----------
Intrinsic Value_5Y_max---3.882----------
Intrinsic Value_5Y_min---12.045----------
Market Cap5515984050.000+39%3370030855.0003219247900.000+5%2047260343.125+65%2156371215.625+56%1768152822.625+91%1274473840.688+164%
Net Profit Margin---1.514-1.253-17%-2.889+91%-3.399+125%49.352-103%24.676-106%
Operating Margin---1.449-1.114-23%-2.714+87%-3.174+119%-63.729+4298%-31.865+2099%
Operating Ratio--2.4372.284+7%3.867-37%4.343-44%64.687-96%32.344-92%
Pb Ratio33.822+39%20.664101.477-80%18.784+10%41.676-50%26.989-23%15.417+34%
Pe Ratio-27.860-64%-17.021-19.090+12%-9.077-47%-11.668-31%-9.466-44%-8.843-48%
Price Per Share86.700+39%52.97050.600+5%32.179+65%33.894+56%27.792+91%20.032+164%
Price To Free Cash Flow Ratio-34.175-64%-20.879-8.557-59%-13.034-38%-9.798-53%-9.468-55%-10.393-50%
Price To Total Gains Ratio-3778.071-64%-2308.240-633.302-73%-15.745-99%-226.622-90%-148.885-94%-114.382-95%
Quick Ratio--4.8356.158-21%8.905-46%9.011-46%14.777-67%16.761-71%
Return On Assets---0.128-0.112-13%-0.237+85%-0.160+25%-0.140+9%-0.223+74%
Return On Equity---0.304-1.349+345%-0.755+149%-0.766+152%-0.509+68%-0.360+19%
Total Gains Per Share---0.0230.409-106%-0.622+2609%-0.092+300%-0.069+199%0.065-135%
Usd Book Value--163089000.00094549000.000+72%152774750.000+7%162511916.667+0%205709000.000-21%163060550.000+0%
Usd Book Value Change Per Share---0.0230.399-106%-0.622+2609%-0.095+315%-0.071+208%0.064-136%
Usd Book Value Per Share--2.5631.486+72%2.401+7%2.554+0%3.233-21%2.563+0%
Usd Dividend Per Share---0.010-100%-0%0.003-100%0.002-100%0.001-100%
Usd Enterprise Value--3460922855.0003245846150.000+7%2143627343.125+61%2262081382.292+53%1930454522.625+79%1876210387.583+84%
Usd Eps---0.778-0.668-14%-1.076+38%-0.818+5%-0.665-14%-0.465-40%
Usd Free Cash Flow---40351000.000-18371750.000-54%-45335500.000+12%-34604916.667-14%-35327550.000-12%-24789050.000-39%
Usd Free Cash Flow Per Share---0.634-0.289-54%-0.713+12%-0.544-14%-0.555-12%-0.390-39%
Usd Free Cash Flow To Equity Per Share---0.1230.574-122%-0.403+227%0.126-198%-0.021-83%0.212-158%
Usd Market Cap5515984050.000+39%3370030855.0003219247900.000+5%2047260343.125+65%2156371215.625+56%1768152822.625+91%1274473840.688+164%
Usd Price Per Share86.700+39%52.97050.600+5%32.179+65%33.894+56%27.792+91%20.032+164%
Usd Profit---49498000.000-42505250.000-14%-68467750.000+38%-52139000.000+5%-42397500.000-14%-29229475.000-41%
Usd Revenue--32704000.00034215750.000-4%22981500.000+42%21866500.000+50%13352500.000+145%6676250.000+390%
Usd Total Gains Per Share---0.0230.409-106%-0.622+2609%-0.092+300%-0.069+199%0.065-135%
 EOD+5 -3MRQTTM+15 -24YOY+30 -73Y+25 -145Y+18 -2210Y+15 -25

3.3 Fundamental Score

Let's check the fundamental score of Rhythm Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-27.860
Price to Book Ratio (EOD)Between0-133.822
Net Profit Margin (MRQ)Greater than0-1.514
Operating Margin (MRQ)Greater than0-1.449
Quick Ratio (MRQ)Greater than14.835
Current Ratio (MRQ)Greater than13.302
Debt to Asset Ratio (MRQ)Less than10.578
Debt to Equity Ratio (MRQ)Less than11.371
Return on Equity (MRQ)Greater than0.15-0.304
Return on Assets (MRQ)Greater than0.05-0.128
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Rhythm Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.928
Ma 20Greater thanMa 5067.180
Ma 50Greater thanMa 10064.408
Ma 100Greater thanMa 20059.874
OpenGreater thanClose89.590
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-12 12:32:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Rhythm Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -151.4% means that $-1.51 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is -151.4%. The company is making a huge loss. -2
  • The TTM is -125.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-151.4%TTM-125.3%-26.1%
TTM-125.3%YOY-288.9%+163.6%
TTM-125.3%5Y4,935.2%-5,060.4%
5Y4,935.2%10Y2,467.6%+2,467.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-151.4%-91.7%-59.7%
TTM-125.3%-140.3%+15.0%
YOY-288.9%-196.4%-92.5%
3Y-339.9%-247.9%-92.0%
5Y4,935.2%-343.3%+5,278.5%
10Y2,467.6%-488.1%+2,955.7%
4.3.1.2. Return on Assets

Shows how efficient Rhythm Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • -12.8% Return on Assets means that Rhythm Pharmaceuticals Inc generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is -12.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.8%TTM-11.2%-1.6%
TTM-11.2%YOY-23.7%+12.5%
TTM-11.2%5Y-14.0%+2.8%
5Y-14.0%10Y-22.3%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.8%-11.5%-1.3%
TTM-11.2%-11.5%+0.3%
YOY-23.7%-11.4%-12.3%
3Y-16.0%-11.7%-4.3%
5Y-14.0%-11.9%-2.1%
10Y-22.3%-13.7%-8.6%
4.3.1.3. Return on Equity

Shows how efficient Rhythm Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • -30.4% Return on Equity means Rhythm Pharmaceuticals Inc generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is -30.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -134.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.4%TTM-134.9%+104.6%
TTM-134.9%YOY-75.5%-59.4%
TTM-134.9%5Y-50.9%-84.0%
5Y-50.9%10Y-36.0%-14.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.4%-13.6%-16.8%
TTM-134.9%-14.8%-120.1%
YOY-75.5%-14.4%-61.1%
3Y-76.6%-16.8%-59.8%
5Y-50.9%-17.5%-33.4%
10Y-36.0%-19.5%-16.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Rhythm Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Rhythm Pharmaceuticals Inc is operating .

  • Measures how much profit Rhythm Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -144.9% means the company generated $-1.45  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is -144.9%. The company is operating very inefficient. -2
  • The TTM is -111.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-144.9%TTM-111.4%-33.5%
TTM-111.4%YOY-271.4%+160.0%
TTM-111.4%5Y-6,372.9%+6,261.5%
5Y-6,372.9%10Y-3,186.5%-3,186.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-144.9%-221.8%+76.9%
TTM-111.4%-250.7%+139.3%
YOY-271.4%-208.5%-62.9%
3Y-317.4%-220.2%-97.2%
5Y-6,372.9%-342.4%-6,030.5%
10Y-3,186.5%-462.5%-2,724.0%
4.3.2.2. Operating Ratio

Measures how efficient Rhythm Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.44 means that the operating costs are $2.44 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is 2.437. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.284. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.437TTM2.284+0.153
TTM2.284YOY3.867-1.583
TTM2.2845Y64.687-62.404
5Y64.68710Y32.344+32.344
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4372.097+0.340
TTM2.2842.684-0.400
YOY3.8673.076+0.791
3Y4.3433.524+0.819
5Y64.6874.724+59.963
10Y32.3446.445+25.899
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Rhythm Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Rhythm Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.30 means the company has $3.30 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is 3.302. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.140. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.302TTM4.140-0.837
TTM4.140YOY5.665-1.525
TTM4.1405Y9.187-5.048
5Y9.18710Y10.692-1.504
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3023.638-0.336
TTM4.1403.846+0.294
YOY5.6654.140+1.525
3Y5.9634.688+1.275
5Y9.1875.722+3.465
10Y10.6926.144+4.548
4.4.3.2. Quick Ratio

Measures if Rhythm Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.84 means the company can pay off $4.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is 4.835. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.158. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.835TTM6.158-1.322
TTM6.158YOY8.905-2.747
TTM6.1585Y14.777-8.620
5Y14.77710Y16.761-1.984
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8352.826+2.009
TTM6.1583.116+3.042
YOY8.9053.786+5.119
3Y9.0114.311+4.700
5Y14.7775.702+9.075
10Y16.7616.335+10.426
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Rhythm Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Rhythm Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rhythm Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.58 means that Rhythm Pharmaceuticals Inc assets are financed with 57.8% credit (debt) and the remaining percentage (100% - 57.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is 0.578. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.756. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.578TTM0.756-0.178
TTM0.756YOY0.527+0.230
TTM0.7565Y0.362+0.394
5Y0.36210Y0.293+0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5780.327+0.251
TTM0.7560.349+0.407
YOY0.5270.332+0.195
3Y0.5320.340+0.192
5Y0.3620.346+0.016
10Y0.2930.378-0.085
4.5.4.2. Debt to Equity Ratio

Measures if Rhythm Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 137.1% means that company has $1.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rhythm Pharmaceuticals Inc:

  • The MRQ is 1.371. The company is able to pay all its debts with equity. +1
  • The TTM is 10.720. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ1.371TTM10.720-9.349
TTM10.720YOY1.414+9.306
TTM10.7205Y2.567+8.153
5Y2.56710Y1.353+1.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3710.383+0.988
TTM10.7200.438+10.282
YOY1.4140.414+1.000
3Y4.1970.450+3.747
5Y2.5670.457+2.110
10Y1.3530.512+0.841
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rhythm Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Rhythm Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -17.02 means the investor is paying $-17.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rhythm Pharmaceuticals Inc:

  • The EOD is -27.860. Based on the earnings, the company is expensive. -2
  • The MRQ is -17.021. Based on the earnings, the company is expensive. -2
  • The TTM is -19.090. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-27.860MRQ-17.021-10.839
MRQ-17.021TTM-19.090+2.069
TTM-19.090YOY-9.077-10.013
TTM-19.0905Y-9.466-9.625
5Y-9.46610Y-8.843-0.623
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.860-2.399-25.461
MRQ-17.021-2.092-14.929
TTM-19.090-2.625-16.465
YOY-9.077-3.784-5.293
3Y-11.668-3.762-7.906
5Y-9.466-6.363-3.103
10Y-8.843-7.055-1.788
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rhythm Pharmaceuticals Inc:

  • The EOD is -34.175. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -20.879. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.557. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-34.175MRQ-20.879-13.296
MRQ-20.879TTM-8.557-12.322
TTM-8.557YOY-13.034+4.477
TTM-8.5575Y-9.468+0.911
5Y-9.46810Y-10.393+0.925
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-34.175-3.299-30.876
MRQ-20.879-2.742-18.137
TTM-8.557-3.801-4.756
YOY-13.034-4.402-8.632
3Y-9.798-5.140-4.658
5Y-9.468-8.483-0.985
10Y-10.393-9.296-1.097
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Rhythm Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 20.66 means the investor is paying $20.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Rhythm Pharmaceuticals Inc:

  • The EOD is 33.822. Based on the equity, the company is expensive. -2
  • The MRQ is 20.664. Based on the equity, the company is expensive. -2
  • The TTM is 101.477. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD33.822MRQ20.664+13.158
MRQ20.664TTM101.477-80.813
TTM101.477YOY18.784+82.693
TTM101.4775Y26.989+74.489
5Y26.98910Y15.417+11.571
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD33.8222.113+31.709
MRQ20.6641.856+18.808
TTM101.4772.125+99.352
YOY18.7842.454+16.330
3Y41.6762.492+39.184
5Y26.9893.668+23.321
10Y15.4174.364+11.053
4.6.2. Total Gains per Share

2.4. Latest News of Rhythm Pharmaceuticals Inc

Does Rhythm Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Rhythm Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-13
00:00
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025Read
2025-07-13
00:00
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025Read
2025-07-12
11:30
Investing.com’s stocks of the weekRead
2025-07-12
11:00
Investing.com’s stocks of the weekRead
2025-07-10
13:04
Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110Read
2025-07-10
12:25
Rhythm Pharmaceuticals prices upsized public offering at $85 per shareRead
2025-07-10
12:21
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockRead
2025-07-09
14:48
Rhythm Pharmaceuticals stock soars on positive Phase 2 obesity drug dataRead
2025-07-09
14:00
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityRead
2025-07-09
14:00
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Rhythm Pharmaceuticals Inc.

4.8.1. Institutions holding Rhythm Pharmaceuticals Inc

Institutions are holding 107.016% of the shares of Rhythm Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc10.77830.00766854755-95960-1.3806
2025-03-31RA Capital Management, LLC9.5675.3824608441200
2025-03-31PRIMECAP Management Company9.09990.25345787322-783868-11.9289
2025-03-31Baker Bros Advisors LP8.81243.28525604483-479766-7.8854
2025-03-31Vanguard Group Inc5.41670.0033344492623260.0676
2025-03-31NEA Management Company, LLC4.575611.8712290995600
2025-03-31Perceptive Advisors LLC4.00714.75622548445-1132028-30.7577
2025-03-31State Street Corp3.09870.004319707331298637.0544
2025-03-31FMR Inc2.65480.0057168837515752661392.6973
2025-03-31HHG PLC2.60280.0497165535043579635.734
2025-03-31Goldman Sachs Group Inc2.57540.0141637908-174298-9.618
2025-03-31Federated Hermes Inc2.5030.18191591871422362.7255
2025-03-31Driehaus Capital Management LLC2.29260.7445145802216704712.9396
2025-03-31Westfield Capital Management Company, L.P.2.10870.3457134109213410920
2025-03-31Geode Capital Management, LLC2.02390.00541287168313692.4979
2025-03-31T. Rowe Price Associates, Inc.1.88540.0078119905351390175.0054
2025-03-31Checkpoint Capital LP1.426526.366290724017925824.624
2025-03-31Rock Springs Capital Management LP1.31172.5282834188-328530-28.2553
2025-03-31Alkeon Capital Management, LLC1.28570.0902817700-350000-29.9735
2025-03-31Hood River Capital Management LLC1.03690.596659431157402.4453
Total 79.063156.498950282430+1089444+2.2%

4.9.2. Funds holding Rhythm Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31PRIMECAP Odyssey Aggressive Growth6.08633.45833870732-604458-13.5069
2025-05-31Vanguard Total Stock Mkt Idx Inv3.09810.0066197033615370.0781
2025-03-31PRIMECAP Odyssey Growth2.5791.85131640202-165100-9.1453
2025-05-31iShares Russell 2000 ETF2.15680.1366137168400
2025-04-30Polar Capital Biotech S Inc1.57243.63991000000500000100
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.28650.045981821656800.699
2025-03-31Federated Hermes Kaufmann Small Cap Grow1.16371.291874006900
2025-03-31Federated Hermes Kaufmann Small Cap A1.16371.29274006900
2025-03-31Federated Hermes Kaufmann Growth1.0870.846569129500
2025-03-31Federated Hermes Kaufmann R1.0870.846669129500
2025-05-31BlackRock Health Sciences Opps Inv A1.08550.656369034700
2025-02-28BGF World Healthscience A21.0680.264467920900
2025-05-31SPDR® S&P Biotech ETF1.04450.868366428439340.5957
2025-03-31BlackRock Health Sciences Term Trust0.99132.310663045900
2024-12-31ACAP Strategic A0.90590.374757614300
2025-03-31Fidelity Small Cap Index0.85930.119854647534360.6327
2025-05-31iShares Russell 2000 Growth ETF0.7460.263447441900
2025-03-31Fidelity Small Cap Growth0.70510.352944840000
2024-09-30UBS: US Equity Small Cap Growth0.66690.785742413100
2025-03-31Hood River Small-Cap Growth Instl0.57490.582736562000
Total 29.927919.994319033385-254971-1.3%

5.3. Insider Transactions

Insiders are holding 0.668% of the shares of Rhythm Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-07-09Hunter C SmithSELL4212080.48
2025-07-09Christopher Paul GermanSELL381780.75
2025-07-09Pamela J CramerSELL1557277.13
2025-07-09Joseph ShulmanSELL796977.78
2025-07-02Alastair GarfieldSELL131964.81
2025-06-10Christopher Paul GermanSELL206967.19
2025-06-06Pamela J CramerSELL703168.05
2025-04-29Pamela J CramerSELL703165.09
2025-04-29Yann MazabraudSELL674565.08
2025-04-08Pamela J CramerSELL2076060.14
2025-04-08Yann MazabraudSELL1775060.99
2025-03-21Christopher Paul GermanSELL34454.23
2025-03-14Yann MazabraudSELL7500051.48
2025-02-19Christopher Paul GermanSELL63557.22
2025-02-19David P MeekerSELL989657.22
2025-02-19Hunter C SmithSELL221557.22
2025-02-19Jennifer Kayden LeeSELL203557.22
2025-02-19Joseph ShulmanSELL122857.22
2025-02-12Jennifer Kayden LeeSELL181556.39
2025-02-11Hunter C SmithSELL129657.51
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets386,685
Total Liabilities223,596
Total Stockholder Equity163,089
 As reported
Total Liabilities 223,596
Total Stockholder Equity+ 163,089
Total Assets = 386,685

Assets

Total Assets386,685
Total Current Assets369,288
Long-term Assets17,397
Total Current Assets
Cash And Cash Equivalents 106,095
Short-term Investments 208,393
Net Receivables 17,825
Inventory 19,316
Other Current Assets 17,659
Total Current Assets  (as reported)369,288
Total Current Assets  (calculated)369,288
+/-0
Long-term Assets
Property Plant Equipment 3,829
Intangible Assets 5,960
Long-term Assets Other 7,608
Long-term Assets  (as reported)17,397
Long-term Assets  (calculated)17,397
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities111,823
Long-term Liabilities111,773
Total Stockholder Equity163,089
Total Current Liabilities
Short-term Debt 224
Accounts payable 11,912
Other Current Liabilities 99,687
Total Current Liabilities  (as reported)111,823
Total Current Liabilities  (calculated)111,823
+/-0
Long-term Liabilities
Capital Lease Obligations 4,063
Long-term Liabilities  (as reported)111,773
Long-term Liabilities  (calculated)4,063
+/- 107,710
Total Stockholder Equity
Common Stock62
Retained Earnings -1,204,836
Other Stockholders Equity 1,223,772
Total Stockholder Equity (as reported)163,089
Total Stockholder Equity (calculated)18,998
+/- 144,091
Other
Capital Stock144,204
Cash and Short Term Investments 314,488
Common Stock Shares Outstanding 63,059
Liabilities and Stockholders Equity 386,685
Net Debt -102,032
Net Invested Capital 18,947
Net Working Capital 257,465
Property Plant and Equipment Gross 3,829
Short Long Term Debt Total 4,063



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312012-12-31
> Total Assets 
18,922
18,186
0
10,687
0
194
327
327
24,690
37,275
0
0
0
12,339
26,033
40,879
34,804
151,736
139,443
291,749
277,728
260,210
236,502
210,888
177,533
308,523
273,756
243,485
215,477
187,073
422,209
388,390
355,823
329,523
284,824
277,675
389,614
382,481
345,678
309,943
354,199
332,745
258,651
381,846
363,572
392,273
386,685
386,685392,273363,572381,846258,651332,745354,199309,943345,678382,481389,614277,675284,824329,523355,823388,390422,209187,073215,477243,485273,756308,523177,533210,888236,502260,210277,728291,749139,443151,73634,80440,87926,03312,33900037,27524,690327327194010,687018,18618,922
   > Total Current Assets 
0
18,139
241
10,649
0
194
168
168
23,957
35,492
34,869
0
0
11,175
24,841
38,937
32,036
150,671
138,414
290,771
276,538
258,689
230,169
203,501
170,877
302,404
267,860
237,819
209,914
181,668
412,134
378,454
335,636
308,387
253,449
249,332
361,874
354,236
317,838
283,878
329,201
308,268
235,753
357,366
340,341
374,200
369,288
369,288374,200340,341357,366235,753308,268329,201283,878317,838354,236361,874249,332253,449308,387335,636378,454412,134181,668209,914237,819267,860302,404170,877203,501230,169258,689276,538290,771138,414150,67132,03638,93724,84111,1750034,86935,49223,957168168194010,64924118,1390
       Cash And Cash Equivalents 
11,766
7,364
-241
8,864
0
152
168
168
23,906
34,869
-34,869
0
0
6,540
11,882
29,198
27,914
34,236
43,167
210,484
58,247
49,542
42,020
63,118
71,680
62,294
55,776
59,091
67,670
100,854
87,271
69,339
92,372
59,248
78,537
113,207
185,087
127,677
109,661
115,684
64,593
60,081
53,428
161,669
47,521
89,137
106,095
106,09589,13747,521161,66953,42860,08164,593115,684109,661127,677185,087113,20778,53759,24892,37269,33987,271100,85467,67059,09155,77662,29471,68063,11842,02049,54258,247210,48443,16734,23627,91429,19811,8826,54000-34,86934,86923,90616816815208,864-2417,36411,766
       Short-term Investments 
5,270
10,398
482
469
0
0
0
0
0
0
69,738
0
0
3,997
12,002
9,017
2,501
113,846
93,286
77,070
214,139
202,519
179,503
132,049
90,755
230,165
201,648
169,535
134,114
71,938
317,479
298,815
235,982
235,607
162,427
122,389
162,708
205,611
184,921
137,918
234,667
215,765
147,771
157,461
250,869
231,428
208,393
208,393231,428250,869157,461147,771215,765234,667137,918184,921205,611162,708122,389162,427235,607235,982298,815317,47971,938134,114169,535201,648230,16590,755132,049179,503202,519214,13977,07093,286113,8462,5019,01712,0023,9970069,73800000046948210,3985,270
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,025
862
1,707
3,328
6,224
8,117
13,831
14,541
14,867
14,695
17,598
19,306
18,512
17,825
17,82518,51219,30617,59814,69514,86714,54113,8318,1176,2243,3281,7078621,025000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
111
108
1,690
1,575
2,917
5,487
6,178
7,762
8,624
8,507
11,994
13,895
18,741
19,316
19,31618,74113,89511,9948,5078,6247,7626,1785,4872,9171,5751,690108111000000000000000000000000000000000
   > Long-term Assets 
0
47
-241
38
0
0
159
159
733
1,783
-34,869
0
0
1,164
1,192
1,942
2,768
1,065
1,029
978
1,190
1,521
6,333
7,387
6,656
6,119
5,896
5,666
5,563
5,405
10,075
9,936
20,187
21,136
31,375
28,343
27,740
28,245
27,840
26,065
24,998
24,477
22,898
24,480
23,231
18,073
17,397
17,39718,07323,23124,48022,89824,47724,99826,06527,84028,24527,74028,34331,37521,13620,1879,93610,0755,4055,5635,6665,8966,1196,6567,3876,3331,5211,1909781,0291,0652,7681,9421,1921,16400-34,8691,7837331591590038-241470
       Property Plant Equipment 
44
24
0
15
0
0
0
0
0
17
0
0
0
930
876
822
845
840
779
728
939
1,120
5,931
6,986
5,959
5,716
5,493
5,263
5,160
5,002
4,747
4,722
4,554
4,335
4,164
3,918
3,699
3,379
3,089
2,763
2,433
2,122
1,819
4,669
4,389
4,109
3,829
3,8294,1094,3894,6691,8192,1222,4332,7633,0893,3793,6993,9184,1644,3354,5544,7224,7475,0025,1605,2635,4935,7165,9596,9865,9311,12093972877984084582287693000017000001502444
       Long Term Investments 
0
0
0
0
0
0
0
0
0
60
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,533
11,815
18,356
15,786
15,616
16,655
16,754
15,518
0
0
0
0
0
0
0
000000015,51816,75416,65515,61615,78618,35611,81510,533000000000000000000000060000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
4,886
4,772
4,658
8,527
8,311
8,097
7,883
7,669
7,456
7,242
7,028
6,815
6,601
6,388
6,174
5,960
5,9606,1746,3886,6016,8157,0287,2427,4567,6697,8838,0978,3118,5274,6584,7724,8865,000000000000000000000000000000000
       Long-term Assets Other 
0
23
-241
23
0
0
159
159
733
1,766
-34,869
0
0
234
316
1,120
1,923
225
250
250
251
401
402
401
697
403
403
403
403
403
328
328
10,533
11,815
18,356
16,114
15,944
16,983
17,082
15,846
15,323
15,327
13,804
12,750
11,992
8,991
7,608
7,6088,99111,99212,75013,80415,32715,32315,84617,08216,98315,94416,11418,35611,81510,5333283284034034034034036974014024012512502502251,9231,12031623400-34,8691,7667331591590023-241230
> Total Liabilities 
2,502
75,646
0
75,025
0
552
730
730
1,920
5,274
0
0
0
5,042
4,167
5,113
5,710
6,948
5,785
7,432
8,091
13,954
16,013
29,421
28,418
27,503
20,655
17,732
18,540
20,545
41,262
36,701
33,560
45,372
49,055
82,047
108,419
118,219
125,915
127,658
156,725
162,986
197,070
342,503
352,357
227,724
223,596
223,596227,724352,357342,503197,070162,986156,725127,658125,915118,219108,41982,04749,05545,37233,56036,70141,26220,54518,54017,73220,65527,50328,41829,42116,01313,9548,0917,4325,7856,9485,7105,1134,1675,0420005,2741,920730730552075,025075,6462,502
   > Total Current Liabilities 
2,502
3,060
0
2,439
0
552
730
730
1,920
5,274
0
0
0
4,731
4,167
4,843
5,460
6,720
5,579
7,247
7,803
13,582
12,567
26,090
25,207
24,417
17,696
14,904
15,848
17,994
16,850
17,459
23,467
43,427
47,274
44,570
33,098
39,809
46,029
46,103
50,144
55,203
54,160
54,722
97,605
115,517
111,823
111,823115,51797,60554,72254,16055,20350,14446,10346,02939,80933,09844,57047,27443,42723,46717,45916,85017,99415,84814,90417,69624,41725,20726,09012,56713,5827,8037,2475,5796,7205,4604,8434,1674,7310005,2741,92073073055202,43903,0602,502
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
404
758
914
944
974
1,006
1,038
1,070
1,106
1,140
1,176
1,212
1,250
644
664
684
705
726
1,496
1,540
793
1,632
0
0
224
224001,6327931,5401,4967267056846646441,2501,2121,1761,1401,1061,0701,0381,0069749449147584040000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002020000000000000000000000
       Accounts payable 
2,245
1,465
0
523
0
535
431
431
949
1,428
0
0
0
1,895
1,491
1,293
2,271
2,427
2,456
3,312
208
7,640
3,992
6,565
7,745
10,415
5,932
4,761
3,793
4,900
9,147
5,009
4,614
5,737
12,010
6,012
4,933
4,797
13,347
8,383
3,839
4,885
7,550
4,543
4,887
12,328
11,912
11,91212,3284,8874,5437,5504,8853,8398,38313,3474,7974,9336,01212,0105,7374,6145,0099,1474,9003,7934,7615,93210,4157,7456,5653,9927,6402083,3122,4562,4272,2711,2931,4911,8950001,428949431431535052301,4652,245
       Other Current Liabilities 
257
1,595
0
1,916
0
17
299
299
971
3,846
0
0
0
2,836
2,676
3,550
3,189
4,293
3,123
3,935
7,595
5,942
8,171
18,767
16,548
13,058
10,790
9,137
11,017
12,024
6,597
11,310
17,677
29,478
24,574
35,605
25,741
32,894
30,549
35,708
43,523
47,492
44,531
47,261
91,432
101,903
99,687
99,687101,90391,43247,26144,53147,49243,52335,70830,54932,89425,74135,60524,57429,47817,67711,3106,59712,02411,0179,13710,79013,05816,54818,7678,1715,9427,5953,9353,1234,2933,1893,5502,6762,8360003,8469712992991701,91601,595257
   > Long-term Liabilities 
0
72,586
0
72,586
0
0
0
0
0
0
0
0
0
311
0
270
250
228
206
185
288
372
3,446
3,331
3,211
3,086
2,959
2,828
2,692
2,551
24,412
19,242
10,093
1,945
1,781
37,477
75,321
78,410
79,886
81,555
106,581
107,783
142,910
287,781
113,271
112,207
111,773
111,773112,207113,271287,781142,910107,783106,58181,55579,88678,41075,32137,4771,7811,94510,09319,24224,4122,5512,6922,8282,9593,0863,2113,3313,446372288185206228250270031100000000072,586072,5860
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,446
0
0
0
0
0
0
0
0
0
0
0
0
35,863
73,881
1,340
1,290
1,320
0
0
0
0
0
0
0
00000001,3201,2901,34073,88135,8630000000000003,4460000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80,950
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000080,9500000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
311
291
680
250
228
206
185
288
372
0
0
0
0
0
0
0
0
22,006
16,984
7,989
0
0
35,863
73,881
77,150
0
0
0
0
0
0
0
0
0
00000000077,15073,88135,863007,98916,98422,006000000003722881852062282506802913110000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
1,481
0
0
0
9
91
895
250
228
206
185
288
372
0
0
295
0
2,959
0
0
0
22,006
16,984
7,989
0
0
0
0
75,810
77,520
79,347
0
0
0
0
0
0
0
000000079,34777,52075,81000007,98916,98422,0060002,9590295003722881852062282508959190001,481000000000
> Total Stockholder Equity
16,420
-57,460
-1,350
-64,338
0
-358
-403
-403
22,770
32,001
32,001
0
0
7,297
21,575
35,766
29,094
144,788
133,658
284,317
269,637
246,256
220,489
181,467
149,115
281,020
253,101
225,753
196,937
166,528
380,947
351,689
322,263
284,151
235,769
195,628
281,195
264,262
219,763
182,285
197,474
169,759
61,581
39,343
11,215
164,549
163,089
163,089164,54911,21539,34361,581169,759197,474182,285219,763264,262281,195195,628235,769284,151322,263351,689380,947166,528196,937225,753253,101281,020149,115181,467220,489246,256269,637284,317133,658144,78829,09435,76621,5757,2970032,00132,00122,770-403-403-3580-64,338-1,350-57,46016,420
   Common Stock
3
53
0
53
0
93
93
93
93
93
0
0
0
10
93
19
2
27
27
34
34
34
34
34
35
44
44
44
44
44
50
50
50
50
50
50
56
56
56
57
59
59
60
60
61
61
62
626161606059595756565650505050505044444444443534343434342727219931000093939393930530533
   Retained Earnings Total Equity0000000-808,940-762,237-710,058-667,565-626,704-581,703-528,939-486,073-450,966-415,577-459,327-424,430-390,612-359,495-325,331-292,375-256,372-213,576-184,602-159,095-141,123-126,711-110,252-99,7210000000000000000
   Accumulated Other Comprehensive Income 
0
8
-1,350
9
0
0
0
0
0
0
-7,999
0
0
-144
0
-60,557
0
0
0
-291,749
0
-809
-809
0
0
-752
-752
630
238
49
-58
21
21
-1
-629
-906
-339
-92
-6
-14
-113
134
-181
-617
-604
-39
-51
-51-39-604-617-181134-113-14-6-92-339-906-629-12121-5849238630-752-75200-809-8090-291,749000-60,5570-14400-7,9990000009-1,35080
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,784
255,013
260,342
425,406
428,698
430,824
434,031
437,805
441,455
606,307
612,552
615,691
621,085
625,762
796,532
802,584
808,265
813,041
818,051
823,188
949,043
974,356
981,950
991,182
0
0
0
0
0
0
0
0000000991,182981,950974,356949,043823,188818,051813,041808,265802,584796,532625,762621,085615,691612,552606,307441,455437,805434,031430,824428,698425,406260,342255,01347,7840000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
917
0
1,006
0
39,147
40,912
40,912
42,229
42,579
0
0
0
43,830
43,910
64,895
47,784
255,013
260,342
425,406
428,698
430,824
434,031
437,805
441,455
606,307
612,552
615,691
621,085
625,762
796,532
802,584
808,265
813,041
818,051
823,188
949,043
974,356
981,950
991,182
1,050,631
1,064,302
1,097,810
827,965
1,123,768
1,177,045
1,223,772
1,223,7721,177,0451,123,768827,9651,097,8101,064,3021,050,631991,182981,950974,356949,043823,188818,051813,041808,265802,584796,532625,762621,085615,691612,552606,307441,455437,805434,031430,824428,698425,406260,342255,01347,78464,89543,91043,83000042,57942,22940,91240,91239,14701,00609170



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue130,126
Cost of Revenue-13,368
Gross Profit116,758116,758
 
Operating Income (+$)
Gross Profit116,758
Operating Expense-382,261
Operating Income-265,503-265,503
 
Operating Expense (+$)
Research Development237,957
Selling General Administrative144,304
Selling And Marketing Expenses0
Operating Expense382,261382,261
 
Net Interest Income (+$)
Interest Income14,711
Interest Expense-20,603
Other Finance Cost-0
Net Interest Income-5,892
 
Pretax Income (+$)
Operating Income-265,503
Net Interest Income-5,892
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-260,256-270,750
EBIT - interestExpense = -260,256
-260,256
-239,999
Interest Expense20,603
Earnings Before Interest and Taxes (EBIT)-239,653-239,653
Earnings Before Interest and Taxes (EBITDA)-238,090
 
After tax Income (+$)
Income Before Tax-260,256
Tax Provision-346
Net Income From Continuing Ops-260,602-260,602
Net Income-260,602
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses395,629
Total Other Income/Expenses Net5,2475,892
 

Technical Analysis of Rhythm Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rhythm Pharmaceuticals Inc. The general trend of Rhythm Pharmaceuticals Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rhythm Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Rhythm Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rhythm Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 69.89 > 60.70 > 58.71.

Know someone who trades $RYTM? Share this with them.👇

Rhythm Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rhythm Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rhythm Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rhythm Pharmaceuticals Inc. The current macd is 5.05744677.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rhythm Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rhythm Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rhythm Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Rhythm Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRhythm Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rhythm Pharmaceuticals Inc. The current adx is 28.50.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Rhythm Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Rhythm Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rhythm Pharmaceuticals Inc. The current sar is 65.99.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Rhythm Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rhythm Pharmaceuticals Inc. The current rsi is 76.93. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending down: The RSI is trending down. -1
Rhythm Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRhythm Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rhythm Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rhythm Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Rhythm Pharmaceuticals Inc Daily Stochastic Oscillator ChartRhythm Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rhythm Pharmaceuticals Inc. The current cci is 225.03.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Rhythm Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRhythm Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rhythm Pharmaceuticals Inc. The current cmo is 60.85.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Rhythm Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRhythm Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rhythm Pharmaceuticals Inc. The current willr is -23.82352941.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Rhythm Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Rhythm Pharmaceuticals Inc Daily Williams %R ChartRhythm Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rhythm Pharmaceuticals Inc. The current atr is 4.08326672.

Rhythm Pharmaceuticals Inc Daily Average True Range (ATR) ChartRhythm Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rhythm Pharmaceuticals Inc. The current obv is 41,948,728.

Rhythm Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRhythm Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rhythm Pharmaceuticals Inc. The current mfi is 81.90.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Rhythm Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRhythm Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rhythm Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Rhythm Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rhythm Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.928
Ma 20Greater thanMa 5067.180
Ma 50Greater thanMa 10064.408
Ma 100Greater thanMa 20059.874
OpenGreater thanClose89.590
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Rhythm Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Rhythm Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rhythm Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rhythm Pharmaceuticals Inc

I send you an email if I find something interesting about Rhythm Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Rhythm Pharmaceuticals Inc.

Receive notifications about Rhythm Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.